Rheopheresis to treat painful skin damage in calciphylaxis
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies whether a treatment called rheopheresis, added to standard care, can help people with calciphylaxis whose skin wounds are getting worse. It may be considered when ulcers or dead (necrotic) skin appear despite conventional treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have calciphylaxis with at least one open ulcer or dead (necrotic) skin area
- You have end-stage kidney disease and receive hemodialysis
- You weigh more than 30 kilograms
- You can give written informed consent (or the study allows it under local rules)
- You have social security coverage (or are a beneficiary of a social security system)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and stores information from people with calciphylaxis, a serious condition that causes painful skin lesions. It may help researchers learn more about the disease and improve future care.
This study tests a new way to do hemodialysis that might remove certain waste products (called protein-bound uremic toxins) more effectively than standard dialysis. It could help people on long-term dialysis feel better and have fewer complications.
This study tests a new drug called EPN-701 for calciphylaxis, a serious condition where calcium deposits damage blood vessels and skin, causing painful sores. If you have this condition and are on regular dialysis, this trial may help reduce your pain and heal your wounds.
This Phase 3 study is for adults on regular dialysis who have a new calciphylaxis ulcer. It tests a better way to give and use treatment guidance so ulcers may improve with clearer, more consistent care.
This trial tests a drug called tocilizumab (an IL-6 blocker) for people with calciphylaxis, a painful skin condition linked to kidney disease. The goal is to see if the drug can reduce inflammation and improve skin sores.
This study looks at a rare condition called calciphylaxis (hardening of small blood vessels) that can happen in people with chronic kidney disease. It aims to learn more about what causes it and how to help those affected.
Hear when a new End Stage Renal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.